The PKM2 sandwich immunoassay developed in this study appears to measure primarily tetrameric PKM2, which is present in the cytosolic fraction. These results are consistent with the changes in PKM2 levels in the cytosolic fraction observed in our previous study on PKM2 activators.

Conclusions

In conclusion, our findings support the potential of PKM2 activators as therapeutic agents for cancer treatment. Further studies are needed to investigate the clinical efficacy of these compounds in various cancer models.

References